The SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus) trial evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. Merck and ARIAD announced results of this Phase III trial at the American Society of Clinical Oncology Meeting in June 2011. Full Press Release here.
